Fully automated radiotherapy treatment planning: A scan to plan challenge.

Autor: Gooding MJ; Inpictura Ltd, 5 The Chambers, Vineyard, Abingdon OX14 3PX, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, M20 4BX Manchester, United Kingdom. Electronic address: mark.gooding@inpicturamedica.com., Aluwini S; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: s.al-uwini@umcg.nl., Guerrero Urbano T; Department of Clinical Oncology Guy's and St Thomas' NHS Foundation Trust School of Cancer and Pharmaceutical Sciences King's College London, London, United Kingdom. Electronic address: teresa.guerrerourbano@gstt.nhs.uk., McQuinlan Y; Mirada Medical Ltd, Barclay House, 234 Botley Road OX2 0HP, United Kingdom. Electronic address: yasmin.mcquinlan@mirada-medical.com., Om D; Department of Medical Physics, Hôpital Européen Georges Pompidou, Université Paris Cité, 75015 Paris, France. Electronic address: deborah.om@aphp.fr., Staal FHE; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: f.h.e.staal@umcg.nl., Perennec T; Département de radiothérapie, Institut de Cancérologie de l'Ouest, Nantes, France. Electronic address: tanguy.perennec@ico.unicancer.fr., Azzarouali S; Radiation Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands. Electronic address: s.azzarouali@amsterdamumc.nl., Cardenas CE; Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: cecardenas@uabmc.edu., Carver A; Department of Medical Physics, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Electronic address: antony.carver@uhb.nhs.uk., Korreman SS; Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark; Danish Center for Particle Therapy, Aarhus University Hospital, 8200 Aarhus N, Denmark. Electronic address: stine.korreman@clin.au.dk., Bibault JE; Department of Radiation Oncology, Hôpital Européen Georges-Pompidou, Université Paris Cité, 75015 Paris, France. Electronic address: jean-emmanuel.bibault@aphp.fr.
Jazyk: angličtina
Zdroj: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Nov; Vol. 200, pp. 110513. Date of Electronic Publication: 2024 Sep 01.
DOI: 10.1016/j.radonc.2024.110513
Abstrakt: Background and Purpose: Over the past decade, tools for automation of various sub-tasks in radiotherapy planning have been introduced, such as auto-contouring and auto-planning. The purpose of this study was to benchmark what degree of automation is possible.
Materials and Methods: A challenge to perform automated treatment planning for prostate and prostate bed radiotherapy was set up. Participants were provided with simulation CTs and a treatment prescription and were asked to use automated tools to produce a deliverable radiotherapy treatment plan with as little human intervention as possible. Plans were scored for their adherence to the protocol when assessed using consensus expert contours.
Results: Thirteen entries were received. The top submission adhered to 81.8% of the minimum objectives across all cases using the consensus contour, meeting all objectives in one of the ten cases. The same system met 89.5% of objectives when assessed with their own auto-contours, meeting all objectives in four of the ten cases. The majority of systems used in the challenge had regulatory clearance (Auto-contouring: 82.5%, Auto-planning: 77%). Despite the 'hard' rule that participants should not check or edit contours or plans, 69% reported looking at their results before submission.
Conclusions: Automation of the full planning workflow from simulation CT to deliverable treatment plan is possible for prostate and prostate bed radiotherapy. While many generated plans were found to require none or minor adjustment to be regarded as clinically acceptable, the result indicated there is still a lack of trust in such systems preventing full automation.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [MJG is shareholder and director of Inpictura Ltd. TGU has institutional funding from Therapanacea for research project (completed). All remaining authors have declared no conflicts of interest].
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: